162740 20251017144621.0 doi 10.1002/cam4.71173 sideral 145212 ART-2025-145212 eng Rubio-Briones, J. Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results 2025 Access copy available to the general public Unrestricted ABSTRACTPatients and MethodsIn this multicenter longitudinal study, data from the Spanish Register in AS (AEU‐PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow‐up strategies.ResultsA total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow‐up visits was 6.03 months. Over a median follow‐up of 62 months (Q1–3: 43.78–85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression‐free survival, metastasis‐free survival, and active treatment‐free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively.ConclusionsMidterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments.Trial RegistrationClinicalTrials.gov identifier: NCT02865330 info:eu-repo/grantAgreement/ES/DGA/T69-23R info:eu-repo/grantAgreement/ES/MICINN/PID2023-150234NB-I00 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Borque-Fernando, A. Universidad de Zaragoza (orcid)0000-0003-0178-4567 Esteban Escaño, L.M. (orcid)0000-0002-3007-302X Wong, A. Guijarro Cascales, A. Gómez Gómez, E. Gil Fabra, J.M. Universidad de Zaragoza (orcid)0000-0002-5629-7646 Sanguedolce, F. Gomez-Veiga, F. López González, P.A. Plata Bello, A. Rodríguez García, N. Montesino Semper, M. Suárez Novo, J.F. Hajianfar, R. Fumadó Ciutat, L.l. González Alfaro, A. Duarte Ojeda, J.M. Bono Ariño, A. Quicios Dorado, C. Loizaga Iriarte, A. García Fadrique, G. Giménez Bachs, J.M. García Barreras, S. Pallas Costa, Y. Vilaseca Cabo, A. Rodrigo Aliaga, M. Campanario Pérez, F. Servián, P. Campá Bortoló, J. M. Soto Delgado, M. Rodríguez de Ledesma, J.M. Sánchez Rodríguez, C. Chantada Abal, V. Hernández Martínez, Y.E. Herrera Imbroda, B. Dolezal, P. Gual Frau, J. Medrano Llorente, P. Moreno Jiménez, J. Serrano Uribe, J.S. Congregado Ruiz, C.B. Reyes, A. Fernández Aparicio, T. García Rodríguez, J. Cuadras Solé, M. García Seguí, A. Pacheco Bru, J.J. Mayor de Castro, J. Mira Moreno, A. Molina Suárez, J.L. 1013 817 Universidad de Zaragoza Dpto. Cirugía Área Urología 14, 17 (2025), e71173 [10 pp.] Cancer med. Cancer medicine 2045-7634 2261312 http://zaguan.unizar.es/record/162740/files/texto_completo.pdf Versión publicada 2399727 http://zaguan.unizar.es/record/162740/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:162740 articulos driver 2025-10-17-14:21:59 ARTICLE